tiprankstipranks
Beam Therapeutics (MX:BEAM)
:BEAM
Mexico Market
BEAM
Beam Therapeutics
RESEARCH TOOLSreports

Beam Therapeutics (BEAM) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

BEAM Analyst Ratings

Strong Buy
11Ratings
Strong Buy
10 Buy
1 Hold
0 Sell
Based on 11 analysts giving stock ratings to
Beam
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

BEAM Stock 12 Month Forecast

Average Price Target

$884.51
▲(76.90% Upside)
Based on 11 Wall Street analysts offering 12 month price targets for Beam Therapeutics in the last 3 months. The average price target is $884.51 with a high forecast of $1,352.97 and a low forecast of $439.72. The average price target represents a 76.90% change from the last price of $500.00.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"324":"$324","1353":"$1,353","581.25":"$581.3","838.5":"$838.5","1095.75":"$1,095.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":1352.9740056,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$1.35K</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":884.506756161,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$884.51</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":439.71655182,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$439.72</span>\n  </div></div>","useHTML":true}}],"tickPositions":[324,581.25,838.5,1095.75,1353],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Dec<br/>2025","6":"Mar<br/>2026","9":"Jun<br/>2026","12":"Sep<br/>2026","25":"Sep<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500,565.6133850461539,631.2267700923077,696.8401551384616,762.4535401846153,828.0669252307692,893.6803102769231,959.2936953230769,1024.9070803692307,1090.5204654153847,1156.1338504615385,1221.7472355076925,1287.3606205538463,{"y":1352.9740056,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500,529.5774427816153,559.1548855632308,588.7323283448461,618.3097711264616,647.8872139080769,677.4646566896923,707.0420994713077,736.6195422529231,766.1969850345384,795.7744278161538,825.3518705977692,854.9293133793847,{"y":884.506756161,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,500,495.3628116784615,490.72562335692305,486.08843503538463,481.45124671384616,476.8140583923077,472.1768700707692,467.5396817492308,462.9024934276923,458.26530510615385,453.6281167846154,448.99092846307695,444.3537401415385,{"y":439.71655182,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":325,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":445,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":475,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":455,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 22,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":485,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":604,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":520,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":520,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":525,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":564.61,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 16,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":628.46,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":436.81,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":500,"date":1788220800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$1,353Average Price Target$884.51Lowest Price Target$439.72
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$1,352.97
Buy
170.59%
Upside
Reiterated
09/09/26
Beam Therapeutics: Buy Rating Reiterated as BEAM-302 Data Strengthens Clinical Profile; $80 Price Target Maintained
JonesTrading Analyst forecast on MX:BEAM
Boris Peaker
JonesTrading
JonesTrading
$591.93
Buy
18.39%
Upside
Reiterated
09/09/26
JonesTrading Remains a Buy on Beam Therapeutics (BEAM)
Canaccord Genuity Analyst forecast on MX:BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$1,319.15
Buy
163.83%
Upside
Reiterated
09/09/26
Canaccord Genuity Keeps Their Buy Rating on Beam Therapeutics (BEAM)
Mizuho Securities Analyst forecast on MX:BEAM
Mara Goldstein
Mizuho Securities
Mizuho Securities
$625.75
Buy
25.15%
Upside
Reiterated
09/09/26
Beam Therapeutics (BEAM) Gets a Buy from Clear Street
William Blair Analyst forecast on MX:BEAM
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Beam Therapeutics: Buy Rating Backed by Strengthened BEAM-302 Clinical Profile and Clearer Accelerated Approval Path Despite Market Pullback
Bank of America Securities Analyst forecast on MX:BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$727.22
Buy
45.44%
Upside
Reiterated
09/08/26
Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Beam Therapeutics (NASDAQ: BEAM) and Royalty Pharma (NASDAQ: RPRX)
J.P. Morgan Analyst forecast on MX:BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
$744.14
Buy
48.83%
Upside
Reiterated
08/06/26
J.P. Morgan Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
Evercore ISI Analyst forecast on MX:BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$761.05
Buy
52.21%
Upside
Reiterated
08/05/26
Evercore ISI Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Wedbush Analyst forecast on MX:BEAM
David Nierengarten
Wedbush
Wedbush
$1,099.29
Buy
119.86%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Wells Fargo Analyst forecast on MX:BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$1,183.85
Buy
136.77%
Upside
Reiterated
08/05/26
Wells Fargo Keeps Their Buy Rating on Beam Therapeutics (BEAM)
RBC Capital Analyst forecast on MX:BEAM
Luca Issi
RBC Capital
RBC Capital
$439.72
Hold
-12.06%
Downside
Reiterated
08/05/26
RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Bernstein Analyst forecast on MX:BEAM
William Pickering
Bernstein
Bernstein
$676.49→$659.57
Buy
31.91%
Upside
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
Citi Analyst forecast on MX:BEAM
Samantha Semenkow
Citi
Citi
$1,150.03
Buy
130.01%
Upside
Reiterated
05/13/26
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
UBS Analyst forecast on MX:BEAM
Michael Yee
UBS
UBS
$473.54
Hold
-5.29%
Downside
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Barclays Analyst forecast on MX:BEAM
Gena Wang
Barclays
Barclays
$355.16
Hold
-28.97%
Downside
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on MX:BEAM
Patrick Trucchio
H.C. Wainwright
H.C. Wainwright
$1,352.97
Buy
170.59%
Upside
Reiterated
09/09/26
Beam Therapeutics: Buy Rating Reiterated as BEAM-302 Data Strengthens Clinical Profile; $80 Price Target Maintained
JonesTrading Analyst forecast on MX:BEAM
Boris Peaker
JonesTrading
JonesTrading
$591.93
Buy
18.39%
Upside
Reiterated
09/09/26
JonesTrading Remains a Buy on Beam Therapeutics (BEAM)
Canaccord Genuity Analyst forecast on MX:BEAM
Whitney Ijem
Canaccord Genuity
Canaccord Genuity
$1,319.15
Buy
163.83%
Upside
Reiterated
09/09/26
Canaccord Genuity Keeps Their Buy Rating on Beam Therapeutics (BEAM)
Mizuho Securities Analyst forecast on MX:BEAM
Mara Goldstein
Mizuho Securities
Mizuho Securities
$625.75
Buy
25.15%
Upside
Reiterated
09/09/26
Beam Therapeutics (BEAM) Gets a Buy from Clear Street
William Blair Analyst forecast on MX:BEAM
Sami Corwin
William Blair
William Blair
―
Buy
―
Reiterated
09/08/26
Beam Therapeutics: Buy Rating Backed by Strengthened BEAM-302 Clinical Profile and Clearer Accelerated Approval Path Despite Market Pullback
Bank of America Securities Analyst forecast on MX:BEAM
Alec Stranahan
Bank of America Securities
Bank of America Securities
$727.22
Buy
45.44%
Upside
Reiterated
09/08/26
Analysts Conflicted on These Healthcare Names: Amgen (NASDAQ: AMGN), Beam Therapeutics (NASDAQ: BEAM) and Royalty Pharma (NASDAQ: RPRX)
J.P. Morgan Analyst forecast on MX:BEAM
Brian Cheng
J.P. Morgan
J.P. Morgan
$744.14
Buy
48.83%
Upside
Reiterated
08/06/26
J.P. Morgan Sticks to Its Buy Rating for Beam Therapeutics (BEAM)
Evercore ISI Analyst forecast on MX:BEAM
Cory Kasimov
Evercore ISI
Evercore ISI
$761.05
Buy
52.21%
Upside
Reiterated
08/05/26
Evercore ISI Reaffirms Their Buy Rating on Beam Therapeutics (BEAM)
Wedbush Analyst forecast on MX:BEAM
David Nierengarten
Wedbush
Wedbush
$1,099.29
Buy
119.86%
Upside
Reiterated
08/05/26
Analysts Offer Insights on Healthcare Companies: Gilead Sciences (NASDAQ: GILD), Ultragenyx Pharmaceutical (NASDAQ: RARE) and Beam Therapeutics (NASDAQ: BEAM)
Wells Fargo Analyst forecast on MX:BEAM
Yanan Zhu
Wells Fargo
Wells Fargo
$1,183.85
Buy
136.77%
Upside
Reiterated
08/05/26
Wells Fargo Keeps Their Buy Rating on Beam Therapeutics (BEAM)
RBC Capital Analyst forecast on MX:BEAM
Luca Issi
RBC Capital
RBC Capital
$439.72
Hold
-12.06%
Downside
Reiterated
08/05/26
RBC Capital Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Bernstein Analyst forecast on MX:BEAM
William Pickering
Bernstein
Bernstein
$676.49→$659.57
Buy
31.91%
Upside
Assigned
05/13/26
Beam Therapeutics price target lowered to $39 from $40 at BernsteinBeam Therapeutics price target lowered to $39 from $40 at Bernstein
Citi Analyst forecast on MX:BEAM
Samantha Semenkow
Citi
Citi
$1,150.03
Buy
130.01%
Upside
Reiterated
05/13/26
Beam Therapeutics: Buy Rating Reaffirmed as Clinical Momentum Builds and $68 Price Target Remains Unchanged
UBS Analyst forecast on MX:BEAM
Michael Yee
UBS
UBS
$473.54
Hold
-5.29%
Downside
Initiated
01/06/26
Beam Therapeutics initiated with a Neutral at UBSBeam Therapeutics initiated with a Neutral at UBS
Barclays Analyst forecast on MX:BEAM
Gena Wang
Barclays
Barclays
$355.16
Hold
-28.97%
Downside
Reiterated
11/05/25
Barclays Keeps Their Hold Rating on Beam Therapeutics (BEAM)
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
ARDXArdelyx
ZVRAZevra Therapeutics
HROWHarrow Health
KURAKura Oncology
SNDXSyndax Pharmaceuticals
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Beam Therapeutics

3 Months
Alec StranahanBank of America Securities
Success Rate
10/15 ratings generated profit
67%
Average Return
+6.75%
Copying Alec Stranahan's trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of +6.75% per trade.
1 Year
Alec StranahanBank of America Securities
Success Rate
11/15 ratings generated profit
73%
Average Return
+27.07%
Copying Alec Stranahan's trades and holding each position for 1 Year would result in 73.33% of your transactions generating a profit, with an average return of +27.07% per trade.
2 Years
Patrick TrucchioH.C. Wainwright
Success Rate
18/21 ratings generated profit
86%
Average Return
+24.33%
Copying Patrick Trucchio's trades and holding each position for 2 Years would result in 85.71% of your transactions generating a profit, with an average return of +24.33% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

BEAM Analyst Recommendation Trends

Rating
May 26
Jun 26
Jul 26
Aug 26
Sep 26
Strong Buy
19
10
9
11
12
Buy
10
6
6
4
7
Hold
1
1
1
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
30
17
16
16
20
In the current month, BEAM has received 19 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. BEAM average Analyst price target in the past 3 months is 884.51.
Each month's total comprises the sum of three months' worth of ratings.

BEAM Financial Forecast

BEAM Earnings Forecast

Next quarter’s earnings estimate for BEAM is -$19.59 with a range of -$21.70 to -$16.99. The previous quarter’s EPS was -$20.03. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s earnings estimate for BEAM is -$19.59 with a range of -$21.70 to -$16.99. The previous quarter’s EPS was -$20.03. BEAM beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Sales Forecast

Next quarter’s sales forecast for BEAM is $148.56M with a range of $0.00 to $538.78M. The previous quarter’s sales results were $8.32M. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.
Next quarter’s sales forecast for BEAM is $148.56M with a range of $0.00 to $538.78M. The previous quarter’s sales results were $8.32M. BEAM beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year BEAM has Performed in-line its overall industry.

BEAM Stock Forecast FAQ

What is MX:BEAM’s average 12-month price target, according to analysts?
Based on analyst ratings, Beam Therapeutics’s 12-month average price target is 884.51.
    What is MX:BEAM’s upside potential, based on the analysts’ average price target?
    Beam Therapeutics has 76.90% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is Beam Therapeutics a Buy, Sell or Hold?
          Beam Therapeutics has a consensus rating of Strong Buy, which is based on 10 buy ratings, 1 hold ratings and 0 sell ratings.
            What is Beam Therapeutics’s share price target?
            The average share price target for Beam Therapeutics is 884.51. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst share price target is $1,352.97 ,and the lowest forecast is $439.72. The average share price target represents 76.90% Increase from the current price of $500.
              What do analysts say about Beam Therapeutics?
              Beam Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 11 Wall Streets Analysts.
                How can I buy shares of Beam Therapeutics?
                To buy shares of MX:BEAM, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.